AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 JUN 3 - (NewsRx.com & NewsRx.net) -- According to a study from Wales, sentinel node biopsy accurately stages axilla in multifocal breast cancer and could become another option in addition to complete axillary lymph node dissection in node-negative patients.
"Multifocal or multicentric breast cancer has been suggested as a contraindication for sentinel node biopsy (SNB). However, recent studies have demonstrated that all quadrants of the breast drain through common afferent channels to a common axillary sentinel node. This should mean that the presence of multifocal tumor should not affect the lymphatic drainage," reasoned A. Goyal and colleagues, reporting on behalf of the ALMANAC Trialists Group in the June 2004 issue of the European Journal of Surgical Oncology.
The researchers' aim was to assess "the feasibility and accuracy of SNB in patients with multifocal breast cancer using a peritumoral injection technique for sentinel lymph node (SN) mapping."
"In the ALMANAC multicenter trial validation phase, we took SNB samples from 842 patients with node-negative, invasive breast cancer with use of a blue dye and radiolabelled colloid mapping technique at the peritumoral injection site. All patients underwent standard axillary treatment after SNB," wrote Goyal and co-authors, who work at the University of Wales College of Medicine.
Histopathology revealed that 75 of the 842 patients have multifocal lesions, and it was ...
Source: HighBeam Research, Sentinel node biopsy accurately stages axilla in multifocal breast...